At the news
? NEUTRALIMPACT 5/10 8-K filed Aug 10, 2026 at 16:18 ET
Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with no revenue surprise. The filing is dominated by operational progress, FDA IND clearance, Phase 2 ASCENTRA-UC trial commencement expected in 2H 2026, and a strong $125.2M cash position funding through key Phase 2 readouts in 2027-2028. The $0.5M milestone license revenue from Newsoara is a modest positive, but the pre-revenue clinical-stage nature of the company makes this a pipeline-progress update rather than a financial catalyst.
- Net loss of $10.6M ($0.05/share) for Q2 2026 vs $2.8M ($0.58/share) in Q2 2025
- Cash and cash equivalents of $125.2M as of June 30, 2026, down from $133.4M at Dec 31, 2025
- FDA clearance of IND for Phase 2 ASCENTRA-UC trial of PALI-2108 received; enrollment expected 2H 2026
- Phase 2 UC primary efficacy readout expected 2H 2027; Phase 2 CD IND expected 2H 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access